To investigate this, we treated sickle Townes mice with GBT1118, a voxelotor analog with pharmacokinetic properties in SCD mice that allows it to achieve the degree of Hb modification voxelotor targets clinically (Dufu et al., 2019), and measured changes in whole blood viscosity, HVR, and RBC deformability during and after cessation of treatment. This evidence concerns the gene GSTM1 and Schnyder corneal dystrophy.